Overview

Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Sao Paulo
Collaborator:
Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP
Treatments:
Acetazolamide
Bevacizumab
Brimonidine Tartrate
Criteria
Inclusion Criteria:

- Diagnosis of age related macular disease or diabetic retinopathy

- Able and willing to provide informed consent

Exclusion Criteria:

- History of ocular hypertension or glaucoma

- High Myopes (> 6 spherical diopters)

- High Hyperopes (> 4 spherical diopters)

- Pulmonary disease

- Renal disease

- Known allergy to any component of the study drug

- Myocardial infarction, transient ischemic attack within 4 months prior to
randomization or any contraindication for bevacizumab use